Cancer Drug Resistance is a gold open-access and quarterly-published journal committed to the rapid publication of high quality, peer-reviewed, original research. The journal publishes research articles, reviews, case reports, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution, and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signalling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification, and DNA repair. Drug classes involved include DNA-targeted drugs and antihormones, as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.